Glooko Collaborates with Johns Hopkins Medicine HealthCare Solutions on Clinically Proven Digital Health Technology for Chronic Conditions

Glooko, Inc., a leading provider of remote patient monitoring and digital health solutions for diabetes and other chronic conditions, today announced a collaboration with Johns Hopkins HealthCare Solutions.

Glooko’s cloud-based, device-agnostic platform and patient app will provide vitals capture and tracking enablement to the Johns Hopkins Blossom™ program, an interactive management program for people with diabetes, offered through employers, health plans and health care providers.

The Blossom solution provides an interactive experience that combines biometric data tracking, personalized skill-building content, and support from coaches to help people with diabetes better assess, understand, and optimize their care and build a healthier lifestyle. Blossom was developed to make diabetes management easier through lifestyle modifications while significantly improving health outcomes and reducing the cost of care.

Glooko is pleased to work with Johns Hopkins HealthCare Solutions to enable a solution that helps patients, employees and health plan members succeed in making positive lifestyle adjustments and improve connections with their care teams, leading to better health,” said Glooko CEO Russ Johannesson. “Opportunities like the Blossom collaboration further expand Glooko’s value and offerings for our health care provider, payer and employer customers. We look forward to continuing to create real and meaningful differences in the lives of people with chronic conditions like diabetes, while reducing the cost of their care.”

Published research has shown that remote patient monitoring coupled with clinically proven behavior change protocols can improve health outcomes among people with diabetes and reduces costs*.

Glooko’s cloud-based digital health platform and patient app integrate seamlessly into the Blossom solution, meeting patients where they are on their journey to better health. Glooko’s data tracking and sharing allows Blossom coaches and customer care teams to provide continuity of care in between doctors’ appointments–through personalized diabetes education content, care coordination and a 365-day coaching program–by identifying and closing any gaps in patient care. The ability to remotely share data also makes it possible to equip care teams with continual data to identify at-risk patients, intervene as needed, and provide more personalized, informed care.

The solution is available to payers, providers and self-insured employers immediately.


References

  1. Tong Sheng, Linda Parks, Sarine Babikian, Vikram Singh, Mark A. Clements. Immediate and Sustained Trends in Glycemic Control during Remote Patient Monitoring in People with Type 2 Diabetes. ADA Scientific Sessions. June 2021
  2. Tong Sheng, Linda Parks, Sarine Babikian, Vikram Singh, Michael Greenfield, Mark A. Clements Glycemic Improvements Following Mobile-Enabled Remote Patient Monitoring: A Randomized Control Study. ADA Scientific Sessions. June 2020.
  3. Mark A Clements, Janelle Duffee, Dawn McCarther. Remote patient monitoring for adults with type 2 diabetes. ADCES Research Sessions. August 2020.
  4. Maureen J. Lage & Kristina S. Boye (2020) The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database, Current Medical Research and Opinion, 36:9, 1441-1447, DOI: 10.1080/03007995.2020.1787971

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”